Venable Fitzpatrick successfully defended the validity of a compound patent covering Sanofi’s Jevtana (cabazitaxel) chemotherapy product before the Federal Circuit.
Venable Fitzpatrick also succeeded in vacating an adverse judgment to Sanofi regarding a second patent that covers a method of treatment for Jevtana, because the district court lacked subject matter jurisdiction. Jevtana is used for the treatment of advanced prostate cancer where other therapies have failed.
Sanofi operates as a pharmaceutical company. The Company, led by Paul Hudson, Jean-Baptiste Chasseloup De Chatillon and Karen Linehan manufactures prescription pharmaceuticals and vaccines. Sanofi also develops cardiovascular, thrombosis, metabolic disorder, central nervous system, and oncology medicines and drugs.
Venable Fitzpatrick advised Sanofi with a team including William E. Solander (Picture), Daniel J. Minion, Dominick A. Conde, Melinda R. Roberts, Whitney L. Meier, Katherine E. Adams, and Nicholas Marcello.
Involved fees earner: Katherine Adams – Venable LLP; Dominick Conde – Venable LLP; Nicholas Marcello – Venable LLP; Whitney Meier – Venable LLP; Daniel Minion – Venable LLP; Melinda Roberts – Venable LLP; William Solander – Venable LLP;
Law Firms: Venable LLP;
Clients: Sanofi S.A.;